Physician profile
Barry M Berman
NPI 1003997545
$1,091.49
in general payments reported to CMS, 2019-2025
14 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $93.36 · 2021: $70.01 · 2022: $130 · 2023: $148 · 2024: $359 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $684.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $329.37 | 2022-2025 | Jakafi, Monjuvi |
| Glaxosmithkline, LLC. | $174.96 | 2019-2025 | Pediarix, Bexsero, Penmenvy |
| Ironshore Pharmaceuticals INC. | $144.41 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $101.77 | 2024-2025 | |
| Corium, LLC | $79.06 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $54.25 | 2020-2022 | |
| Hologic Sales and Service, LLC | $48.99 | 2024 | Aptima |
| Pfizer INC. | $29.89 | 2023 | |
| Supernus Pharmaceuticals, INC. | $28.51 | 2023 | Qelbree |
| Adlon Therapeutics L.P. | $28.40 | 2020-2021 | |
| Tris Pharma INC | $25.85 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $19.17 | 2022 | |
| Seqirus USA INC | $13.63 | 2025 | Flucelvax |
| Merck Sharp & Dohme LLC | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.